FierceBiotechOriginal article
{"a":[{"_":"Merck’s $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trials","$":{"href":"/biotech/mercks-11b-asset-delivers-1-win-1-loss-midphase-inflammatory-disease-trials","hreflang":"en"}}]}
Phase 2Mixedanti-TL1A monoclonal antibodyNegative
AI Analysis
Summary
Merck's anti-TL1A monoclonal antibody, acquired for $10.8 billion, missed its primary endpoint in a Phase 2 inflammatory disease trial, but achieved a positive result in another midphase indication.
Clinical Trial Data
Phase
2
Primary Endpoint
Not Met
Outcome Details
Phase 2 trial missed primary endpoint in one indication but achieved a win in another midphase indication
Importance:7/10
Sentiment:
-0.30
Phase 2 DataInflammatory DiseaseMonoclonal AntibodyAcquisitionPrimary Endpoint Missed
Related Companies
Read the original article
Published by FierceBiotech on August 4, 2026 4:13 AM